cEt KRAS antisense oligonucleotide AZD4785

{
  "id": "MLC-T-ONC-012531",
  "term": "cEt KRAS antisense oligonucleotide AZD4785",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2'-4' constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.",
  "synonyms": [
    "cEt KRAS ASO AZD4785",
    "ASO AZD4785",
    "generation 2.5 drug AZD4785",
    "IONIS-KRAS-2.5Rx"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cet-kras-antisense-oligonucleotide-azd4785/"
}